UBS Group’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $16.5M | Buy |
|
|||||
|
2025
Q2 | $16M | Sell |
|
|||||
|
2025
Q1 | $17M | Buy |
|
|||||
|
2024
Q4 | $13.7M | Buy |
|
|||||
|
2024
Q3 | $5.17M | Sell |
|
|||||
|
2024
Q2 | $8.05M | Buy |
|
|||||
|
2024
Q1 | $7.9M | Buy |
|
|||||
|
2023
Q4 | $2.77M | Buy |
|
|||||
|
2023
Q3 | $1.65M | Sell |
|
|||||
|
2023
Q2 | $2.93M | Sell |
|
|||||
|
2023
Q1 | $3.01M | Sell |
|
|||||
|
2022
Q4 | $7.65M | Buy |
|
|||||
|
2022
Q3 | $1.23M | Sell |
|
|||||
|
2022
Q2 | $2.81M | Sell |
|
|||||
|
2022
Q1 | $6.71M | Buy |
|
|||||
|
2021
Q4 | $5.33M | Buy |
|
|||||
|
2021
Q3 | $5.07M | Buy |
|
|||||
|
2021
Q2 | $2.44M | Sell |
|
|||||
|
2021
Q1 | $5.65M | Buy |
|
|||||
|
2020
Q4 | $3.83M | Buy |
|
|||||
|
2020
Q3 | $2.15M | Sell |
|
|||||
|
2020
Q2 | $2.48M | Sell |
|
|||||
|
2020
Q1 | $5.81M | Buy |
|
|||||
|
2019
Q4 | $3.51M | Sell |
|
|||||
|
2019
Q3 | $7.03M | Buy |
|
|||||
|
2019
Q2 | $2.54M | Buy |
|
|||||
|
2019
Q1 | $1.97M | Sell |
|
|||||
|
2018
Q4 | $6.51M | Buy |
|
|||||
|
2018
Q3 | $3.16M | Buy |
|
|||||
|
2018
Q2 | $2.17M | Sell |
|
|||||
|
2018
Q1 | $5.82M | Buy |
|
|||||
|
2017
Q4 | $1.11M | Sell |
|
|||||
|
2017
Q3 | $1.89M | Buy |
|
|||||
|
2017
Q2 | $1.07M | Buy |
|
|||||
|
2017
Q1 | $658K | Sell |
|
|||||
|
2016
Q4 | $3.28M | Buy |
|
|||||
|
2016
Q3 | $2.13M | Buy |
|
|||||
|
2016
Q2 | $1.32M | Buy |
|
|||||
|
2016
Q1 | $841K | Sell |
|
|||||
|
2015
Q4 | $1.92M | Buy |
|
|||||
|
2015
Q3 | $977K | Sell |
|
|||||
|
2015
Q2 | $2.92M | Buy |
|
|||||
|
2015
Q1 | $606K | Buy |
|
|||||
|
2014
Q4 | $419K | Buy |
|